News
Public · Published
Zevra Therapeutics Reports Q3 2026 Revenue of $37.8M and Net Income of $19.2M
Zevra Therapeutics reported third-quarter 2026 revenue of $37.8 million, up 45% from a year earlier, and net income of $19.2 million. Diluted earnings were $0.26 per share, compared with a $0.01-per-share loss in Q3 2025. The company reported $270.9 million in cash, equivalents and investments at September 30, 2026.
Published:
Updated:
What happened
Zevra Therapeutics reported third-quarter 2026 revenue of $37.8 million, up 45% from a year earlier, and net income of $19.2 million. Diluted earnings were $0.26 per share, compared with a $0.01-per-share loss in Q3 2025. The company reported $270.9 million in cash, equivalents and investments at September 30, 2026.
Confirmed
Global impact / market context
Revenue growth and a return to reported profit could strengthen Zevra’s ability to fund operations and commercial activity without immediately relying on new financing. However, the $19.2 million net income included $5.1 million of noncash gains from liability value adjustments, so it does not all represent cash generated.
Analyst inference
MIPLYFFA generated $34.0 million of the quarter’s $37.8 million revenue, making reported sales heavily concentrated in that product. Investors may therefore focus on whether its prescriptions and revenue continue to grow; the supplied article gives 13 new enrollment forms but no complete cumulative total.
Analyst inference
What to watch
- Track future MIPLYFFA revenue and prescription enrollment forms: continued growth would support sales, while slower uptake could weaken the main reported source of quarterly revenue. Analyst inference
- Compare future net income with operating income and cash levels, since the reported quarter included $5.1 million of noncash gains from liability value adjustments. Analyst inference
- The article reports $270.9 million in cash, equivalents and investments at September 30, 2026; later reports can show how this balance changes as operations continue. Confirmed
Evidence
- Original source link unavailable